Paion "buy" (Seite 6955)
eröffnet am 12.07.05 19:39:23 von
neuester Beitrag 12.04.24 13:32:35 von
neuester Beitrag 12.04.24 13:32:35 von
Beiträge: 123.397
ID: 992.863
ID: 992.863
Aufrufe heute: 56
Gesamt: 16.514.385
Gesamt: 16.514.385
Aktive User: 0
ISIN: DE000A3E5EG5 · WKN: A3E5EG · Symbol: PA8
0,0282
EUR
-17,06 %
-0,0058 EUR
Letzter Kurs 18:31:17 Tradegate
Neuigkeiten
22.12.23 · 4investors |
22.12.23 · wO Newsflash |
22.12.23 · EQS Group AG |
24.11.23 · 4investors |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 50,50 | +87,04 | |
| 1,9000 | +59,66 | |
| 0,6000 | +57,48 | |
| 1,3500 | +29,82 | |
| 1,5700 | +25,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3000 | -17,27 | |
| 3,0200 | -23,54 | |
| 2,7900 | -24,80 | |
| 5,2000 | -33,33 | |
| 9,6200 | -33,70 |
Beitrag zu dieser Diskussion schreiben
Feedback
Also bei 2.15€ wird mein rechter Zeigefinger böse zucken 
Antwort auf Beitrag Nr.: 48.298.552 von mfierke am 12.11.14 15:21:04Kann sein, muss nicht sein. Mir ist das Risiko für die eventuell kurfristig möglichen 5% Gewinn einfach zu hoch.
Antwort auf Beitrag Nr.: 48.298.495 von vitello am 12.11.14 15:16:30so sehe ich das auch, ich stand bei 2,26, habe sie wieder rausgenommen, denke auch, das es noch tiefer geht.
Antwort auf Beitrag Nr.: 48.298.399 von mfierke am 12.11.14 15:05:20Steht noch weitaus tiefer 
Mag zwar auch Sinn machen, bei 2,25 einzusteigen und auf nochmaligen Sprung auf 2,40 zu hoffen, aber in der momentanen Stimmungslage bleib ich da mal vorsichtig.
Mag zwar auch Sinn machen, bei 2,25 einzusteigen und auf nochmaligen Sprung auf 2,40 zu hoffen, aber in der momentanen Stimmungslage bleib ich da mal vorsichtig.
Antwort auf Beitrag Nr.: 48.298.309 von vitello am 12.11.14 14:56:26wo steht dein Körbchen denn, gerade wurde sie bis auf 2,22 runter geprügelt
Trading Spotlight
Antwort auf Beitrag Nr.: 48.297.310 von ariba0815 am 12.11.14 13:43:17auch dieser Artikel zeigt, dass weltweit an und mit Remi gearbeitet wird; auch wenn die Allgemeinheit und wir es nicht immer mitbekommen. Sogar in Bereichen in denen man es garnicht annehmen würde, wie ich es bereits in meinem Beitrag vor mehreren Monaten geschrieben hatte. Denn da wurden in den USA bereits die Narkose-Schwestern bei ihrer Tagung auf Remi aufmerksam gemacht.
Da braucht der neue Vertriebschef von Paion in den USA wenigsten nicht ganz von vorne anfangen.
Es sieht so aus als würde es eine lange Zeit dauern bis eindeutig Stellung bezogen wird für ein Medikament, das ein bereits eingeführtes ablösen kann/soll. Daher ist der Ausgang für Remi wohl immer noch ungewiss!
Sehen sie daher auch den Beitrag vom 13. März 2013
Anesthetic drug development: Novel drugs and new approaches
Hovig V. Chitilian, Roderic G. Eckenhoff,1 and Douglas E. Raines*
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA
1Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Hovig V. Chitilian: gro.srentrap@nailitihch; Roderic G. Eckenhoff: ude.nnepu.shpu@ffohnekce.ciredor; Douglas E. Raines: gro.srentrap@seniard
*Corresponding author
Remimazolam (CNS 7056)
Remimazolam is an analogue of midazolam that utilizes the metabolically labile ester design approach to produce an ultra-short–acting benzodiazepine [Figure 2]. Remimazolam is rapidly hydrolyzed by nonspecific esterases to the carboxylic acid CNS 7054, which has an in vitro affinity for human GABAA receptors that is 400-fold lower than remimazolam.[31] Thus, the metabolite is not expected to produce important behavioral effects unless it accumulates with prolonged remimazolam administration and achieves high brain concentrations. Studies in animals have confirmed that remimazolam is a potent hypnotic, is rapidly metabolized, and has a significantly shorter duration of action than midazolam. In mice, for example, approximately equihypnotic doses of remimazolam and midazolam produce loss of righting reflexes for durations of several minutes and nearly an hour, respectively.[31] Remimazolam produces modest respiratory and cardiovascular depression at sedating doses, a side effect profile that it shares with midazolam and other benzodiazepines.[61,60]
Figure 2
Remimazolam is a benzodiazepine that contains a metabolically labile ester moiety that renders it ultra-short acting. JM-1232(-) is a benzodiazepine-like sedative–hypnotic with a very high therapeutic index
Phase 1 clinical trials to assess the safety and efficacy of remimazolam have been completed and the results reported. These studies showed that remimazolam is more rapidly metabolized than midazolam and recovery is faster, consistent with prior studies in animals. Following 1-min intravenous infusions of remimazolam and midazolam (at equihypnotic doses), recovery times were 10 and 40 min, respectively.[1] This difference is less than that observed in mice, which may reflect differences between mice and humans in the rates with which they metabolize ester-containing soft drugs. Pharmacokinetic/pharmacodynamic modeling studies of remimazolam and midazolam suggest that even larger differences between the 2 drugs would be observed following prolonged infusion.[66] In the case of midazolam, the context-sensitive half-time (the time required for blood concentrations to decrease by half after infusion termination) is predicted to increase dramatically with midazolam infusion length, reaching 60 min after a simulated 8-h infusion.[66] In contrast, the predicted context-sensitive half-time of remimazolam reaches a maximum of only 7-8 min for infusions longer than 2 h. In these modeling studies, hypnotic recovery was also predicted to be highly dependent on infusion duration for midazolam, reaching 6 h after an 8-h infusion, whereas predicted recovery was essentially independent of infusion duration for remimazolam infusions greater than 2 h.
Based on the existing data, remimazolam shows great promise as a sedative agent for outpatient procedural sedation where predictable and rapid recovery is highly desirable. The ability to pharmacologically reverse its actions when inadvertent over-dosage leads to significant respiratory depression is also highly desirable, particularly when administered by practitioners who are not highly trained in airway management. Further human studies are needed to more completely characterize its action, to define optimal dosing regimens, and to determine whether metabolite accumulation with prolonged infusion slows recovery, particularly in patients with renal dysfunction.
Da braucht der neue Vertriebschef von Paion in den USA wenigsten nicht ganz von vorne anfangen.
Es sieht so aus als würde es eine lange Zeit dauern bis eindeutig Stellung bezogen wird für ein Medikament, das ein bereits eingeführtes ablösen kann/soll. Daher ist der Ausgang für Remi wohl immer noch ungewiss!
Sehen sie daher auch den Beitrag vom 13. März 2013
Anesthetic drug development: Novel drugs and new approaches
Hovig V. Chitilian, Roderic G. Eckenhoff,1 and Douglas E. Raines*
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA
1Department of Anesthesiology and Critical Care, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Hovig V. Chitilian: gro.srentrap@nailitihch; Roderic G. Eckenhoff: ude.nnepu.shpu@ffohnekce.ciredor; Douglas E. Raines: gro.srentrap@seniard
*Corresponding author
Remimazolam (CNS 7056)
Remimazolam is an analogue of midazolam that utilizes the metabolically labile ester design approach to produce an ultra-short–acting benzodiazepine [Figure 2]. Remimazolam is rapidly hydrolyzed by nonspecific esterases to the carboxylic acid CNS 7054, which has an in vitro affinity for human GABAA receptors that is 400-fold lower than remimazolam.[31] Thus, the metabolite is not expected to produce important behavioral effects unless it accumulates with prolonged remimazolam administration and achieves high brain concentrations. Studies in animals have confirmed that remimazolam is a potent hypnotic, is rapidly metabolized, and has a significantly shorter duration of action than midazolam. In mice, for example, approximately equihypnotic doses of remimazolam and midazolam produce loss of righting reflexes for durations of several minutes and nearly an hour, respectively.[31] Remimazolam produces modest respiratory and cardiovascular depression at sedating doses, a side effect profile that it shares with midazolam and other benzodiazepines.[61,60]
Figure 2
Remimazolam is a benzodiazepine that contains a metabolically labile ester moiety that renders it ultra-short acting. JM-1232(-) is a benzodiazepine-like sedative–hypnotic with a very high therapeutic index
Phase 1 clinical trials to assess the safety and efficacy of remimazolam have been completed and the results reported. These studies showed that remimazolam is more rapidly metabolized than midazolam and recovery is faster, consistent with prior studies in animals. Following 1-min intravenous infusions of remimazolam and midazolam (at equihypnotic doses), recovery times were 10 and 40 min, respectively.[1] This difference is less than that observed in mice, which may reflect differences between mice and humans in the rates with which they metabolize ester-containing soft drugs. Pharmacokinetic/pharmacodynamic modeling studies of remimazolam and midazolam suggest that even larger differences between the 2 drugs would be observed following prolonged infusion.[66] In the case of midazolam, the context-sensitive half-time (the time required for blood concentrations to decrease by half after infusion termination) is predicted to increase dramatically with midazolam infusion length, reaching 60 min after a simulated 8-h infusion.[66] In contrast, the predicted context-sensitive half-time of remimazolam reaches a maximum of only 7-8 min for infusions longer than 2 h. In these modeling studies, hypnotic recovery was also predicted to be highly dependent on infusion duration for midazolam, reaching 6 h after an 8-h infusion, whereas predicted recovery was essentially independent of infusion duration for remimazolam infusions greater than 2 h.
Based on the existing data, remimazolam shows great promise as a sedative agent for outpatient procedural sedation where predictable and rapid recovery is highly desirable. The ability to pharmacologically reverse its actions when inadvertent over-dosage leads to significant respiratory depression is also highly desirable, particularly when administered by practitioners who are not highly trained in airway management. Further human studies are needed to more completely characterize its action, to define optimal dosing regimens, and to determine whether metabolite accumulation with prolonged infusion slows recovery, particularly in patients with renal dysfunction.
wo steht es denn vitelo?
ob mein Körbchen doch noch bedient wird? Heute? Oder erst morgen? 
Der / Die Artikel kommen unter anderen vom
US National Library of Medicine National Institutes of Health
wie z.B. ein Artikel
Anesth Analg. 2012 Aug;115(2):274-83. doi: 10.1213/ANE.0b013e31823f0c28. Epub 2011 Dec 20.
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
Antonik LJ1, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM.
Author information
1Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Alles sehr angesehene Mediziner.
f_moll
US National Library of Medicine National Institutes of Health
wie z.B. ein Artikel
Anesth Analg. 2012 Aug;115(2):274-83. doi: 10.1213/ANE.0b013e31823f0c28. Epub 2011 Dec 20.
A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
Antonik LJ1, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM.
Author information
1Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Alles sehr angesehene Mediziner.
f_moll
Antwort auf Beitrag Nr.: 48.297.727 von Baumriese am 12.11.14 14:16:35
Wenn Du Hirn brauchst dann bitte .....
Besser geht es nicht sich selbst darzustellen.
f_moll
Zitat von Baumriese: Ach so...hmmm, dann war CENES also auch 2013 noch "Aktuell"???? und PAION einfach nur PAION....oder wie jetzt????? und wo war Remi die ganze Zeit???
....und aus Arabien kommt ja sowieso nix Gutes...(wer hat's erfunden)...
....und einen "Markt" für Anästhesie gibt es dort bestimmt auch nicht...
....und eingestellt und publiziert wurde der Artikel "nur" im U.S. National Institutes of Health's National Library of Medicine (NIH/NLM)....
hmmm, ach so ist ja alles eh nur "Schnee von Gestern" (Sept. 2014)...
Oh Herr, schmeiß Hirn vom Himmel, aber ganz ordentlich....
Grüße aus dem Wald,
BR
Wenn Du Hirn brauchst dann bitte .....
Besser geht es nicht sich selbst darzustellen.
f_moll
Durchsuchen
Paion "buy"
